SynBioBeta Speaker
Andrew Han
Ion Genomics
Editor
Andrew P. Han is a journalist with Retraction Watch. He has written about synthetic DNA, CRISPR, DNA sequencing, and bioinformatics — including new AI-based virtual cell models, among other topics.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Andrew
This Year
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Featuring
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Christopher Vakulskas
Integrated DNA Technologies
Sr. Dir. of Enzyme Dev.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
Andrew Han
Ion Genomics
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
•
-
Tools & Tech
Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?
For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.
Featuring
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Emily Leproust
Twist Bioscience
CEO
Leader in DNA Manufacturing, put DNA writing on silicon.
Christopher Vakulskas
Integrated DNA Technologies
Sr. Dir. of Enzyme Dev.
Monique Coy
Corteva Agriscience
Program Leader
Jodi Barrientos
Ribbon Bio
CEO
Andrew Han
Ion Genomics
Editor
GenomeWeb editor covering sequencing and diagnostics markets.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
